MONOPAR THERAPEUTICS (MNPR) News
Filter MNPR News Items
MNPR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
MNPR News Highlights
- MNPR's 30 day story count now stands at 3.
- Over the past 10 days, the trend for MNPR's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about MNPR are MASI and PCRX.
Latest MNPR News From Around the Web
Below are the latest news stories about Monopar Therapeutics that investors may wish to consider to help them evaluate MNPR as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayWith the long weekend over it's time to start another week of trading with the biggest pre-market stock movers for Tuesday! |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayGood morning! |
Analysts Offer Insights on Healthcare Companies: Masimo (MASI), Pacira Pharmaceuticals (PCRX) and Monopar Therapeutics Inc (MNPR)Analysts have been eager to weigh in on the Healthcare sector with new ratings on Masimo (MASI – Research Report), Pacira Pharmaceuticals (PCRX – Research Report) and Monopar Therapeutics Inc (MNPR – Research Report). Masimo (MASI) BTIG analyst Marie Thibault maintained a Hold rating on Masimo today. The company's shares closed last Tuesday at $228.84. According to TipRanks. |
Monopar Announces Clinical and Preclinical Program UpdatesValidive Phase 2b/3 VOICE trial now open at 43 sites; active and enrolling in US and EU Open-label Phase 1b camsirubicin trial: early signs of clinical benefit observed WILMETTE, Ill., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced program updates across its pipeline and anticipated 2022 |
Maxim Group Thinks Monopar Therapeutics Inc’s Stock is Going to RecoverMaxim Group analyst Jason McCarthy maintained a Buy rating on Monopar Therapeutics Inc (MNPR – Research Report) on February 2 and set a price target of $8.00. The company's shares closed last Friday at $2.76, close to its 52-week low of $2.36. According to TipRanks.com, McCarthy 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -22.9% and a 14.7% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Reviva Pharmaceuticals Holdings, and Brainstorm Cell Therapeutics. Currently, the analyst consensus on Monopar Therapeutics Inc is a Strong Buy with an average price target of $16.67. |
Monopar to Present at the H.C. Wainwright BioConnect ConferenceWILMETTE, Ill., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ: MNPR ), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler Robinson, MD, Monopar''s Chief Executive Officer, will present at the H.C. Wainwright BioConnect Conference. The presentation will be available Full story available on Benzinga.com |
-$0.18 Earnings Per Share Expected for Monopar Therapeutics Inc. (NASDAQ:MNPR) This QuarterWall Street brokerages predict that Monopar Therapeutics Inc. (NASDAQ:MNPR) will report ($0.18) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Monopar Therapeutics earnings. The highest EPS estimate is ($0.16) and the lowest is ($0.20). Monopar Therapeutics reported earnings per share of ($0.19) during the same quarter last [] |
Zacks: Brokerages Expect Monopar Therapeutics Inc. (NASDAQ:MNPR) to Post -$0.18 Earnings Per ShareBrokerages expect Monopar Therapeutics Inc. (NASDAQ:MNPR) to announce ($0.18) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Monopar Therapeutics earnings, with estimates ranging from ($0.20) to ($0.16). Monopar Therapeutics posted earnings of ($0.19) per share in the same quarter last year, which indicates a [] |
Monopar Therapeutics Inc (MNPR) Gets a Buy Rating from JonesTradingJonesTrading analyst Soumit Roy reiterated a Buy rating on Monopar Therapeutics Inc (MNPR – Research Report) today and set a price target of $33.00. The company's shares closed last Tuesday at $4.00, close to its 52-week low of $3.70. According to TipRanks.com, Roy is a 5-star analyst with an average return of 20.5% and a 35.8% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Actinium Pharmaceuticals, and Adaptimmune Therapeutics. Currently, the analyst consensus on Monopar Therapeutics Inc is a Strong Buy with an average price target of $17.67. See Insiders’ Hot Stocks on TipRanks >> The company has a one-year high of $17. |
JonesTrading Thinks Monopar Therapeutics Inc’s Stock is Going to RecoverIn a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Monopar Therapeutics Inc (MNPR – Research Report), with a price target of $33.00. The company's shares closed last Tuesday at $3.82, close to its 52-week low of $3.70. According to TipRanks.com, Roy is a 5-star analyst with an average return of 21.3% and a 36.3% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Adaptimmune Therapeutics, and Actinium Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Monopar Therapeutics Inc with a $17.67 average price target. |